Low-dose dasatinib seems to be safe and effective in intolerant patients with CML

Low-dose dasatinib seems to be safe and effective in intolerant patients with chronic phase (CP) chronic myelogenous leukaemia (CML), two case reports and review of the literature showed. The lower-dose therapy may be considered before stopping or switching treatment.